Rhizome AI

Roadmap & Position in Life Sciences

Hallucination-free, citation-backed FDA regulatory intelligence for pharma and biotech.

Company Overview

Builds an AI-powered regulatory intelligence platform that uses retrieval-augmented generation and graph databases to deliver citation-backed, hallucination-free answers to complex FDA and global health authority questions for pharma, biotech, and medtech teams.

What They're Building

The company's public product roadmap & what they're committed to building.

Rhizome AI reads up to 1,000 documents per question, accompanies each statement with a citation, and draws on 2.5TB of public data from FDA, EMA, MHRA, PMDA of Japan, and global clinical trial registries. Published pricing tiers (Project, Professional, Business, Enterprise) signal a land-and-expand GTM strategy. Exhibited at DIA RDISM 2026 conference. Expanding to additional regulatory authorities (Health Canada) and deeper postmarket/real-world evidence datasets.

Latest Intelligence

Zeitgeist tracks private signals to determine where the company is heading strategically.

Competitors

Regulatory Intelligence Platforms

Veeva Vault RIM, Citeline (Pharma Intelligence), Cortellis (Clarivate).

Regulatory Consulting

Regulatory Compliance Associates (RCA), PAREXEL.

AI-Native Competitors

Lucem Health, various stealth regulatory AI startups.

Traditional Search

Manual FDA.gov search, legal databases (Westlaw, LexisNexis for regulatory).

Rhizome AI

's Moat:

2.5TB of regulatory data indexed across FDA, EMA, MHRA, and PMDA with word-level citations. Zero hallucination tolerance via graph databases and RAG is a compliance requirement, not a feature. EvolutionaryScale founding product engineer as a builder means the AI infrastructure experience is frontier-grade. 18 organizations as early customers validates demand.

How They're Leveraging AI

AI Use Overview:

Using retrieval-augmented generation from 1,000+ regulatory documents, knowledge graph intelligence for entity relationships, and document processing pipelines.

More Similar Companies

10xScience

Turns weeks of manual protein analysis into minutes for drug development teams.

CellType

Simulates human biology with AI to predict drug effects and run virtual trials.

Google CEO Sundar Pichai highlighted their C2S-Scale 27B model for generating a novel cancer hypothesis that was later validated experimentally. CellType simulates human biology to predict drug effects using foundation models presented at ICML 2024, with all deals coming inbound from top-10 pharma. Yale professor turned down Google to build it.

Ditto Biosciences

Mines parasite genomes to discover protein therapeutics for autoimmune diseases.

Parasites evolved to suppress human immune responses over millions of years. Ditto mines their genomes for immunomodulatory proteins, and over 98% of those proteins remain uncharacterized. Three PhDs from Harvard, Berkeley, and UCSF with 40+ years of combined expertise in host-parasite biology.

Mango Medical

Automates surgical planning for orthopedic procedures from CT scans using agentic AI.

Surgical planning for shoulder replacements takes hours of manual CT scan interpretation. Mango automates it in seconds via API, already past $500K ARR before demo day, with an 8-figure LOI from a leading orthopedic company. Only company in YC W26 pursuing FDA 510(k) clearance.